Singapore markets closed

Vaxart, Inc. (VXRT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
4.7950-0.2550 (-5.05%)
At close: 04:00PM EST
4.8000 +0.01 (+0.10%)
After hours: 07:59PM EST
Full screen
Trade prices are not sourced from all markets
Previous close5.0500
Bid4.7900 x 1800
Ask4.8000 x 1200
Day's range4.5200 - 5.1000
52-week range4.5200 - 24.9000
Avg. volume3,477,390
Market cap601.753M
Beta (5Y monthly)0.25
PE ratio (TTM)N/A
EPS (TTM)-0.5410
Earnings date23 Feb 2022 - 28 Feb 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend date09 Nov 2012
1y target est12.00
  • Yahoo Finance Video

    BioMarin CEO: There are biotech companies 'that probably should not be on the market today’

    BioMarin CEO JJ Bienaimé joins Yahoo Finance Live’s Julie Hyman and Anjalee Khemlani to discuss the company's first gene therapy product targeted to patients dealing with hemophilia, the future of biotechnology, biotech stocks, and key takeaways from JPMorgan’s annual health care conference.

  • Motley Fool

    Which Vaccine Stocks Will Make You a Fortune in 2022?

    For example, Novavax (NASDAQ: NVAX) soared 2,700% in 2020. Of course, it's impossible to predict with 100% certainty which companies will succeed in the vaccine race -- and whether their share prices will skyrocket. Gritstone Bio (NASDAQ: GRTS) is developing an mRNA vaccine candidate.

  • Motley Fool

    Is This Vaccine Stock a Buy?

    The recent surge in COVID-19 cases caused by the new and more contagious omicron variant of the coronavirus has taught us at least one thing: There's still a dire need for effective vaccines against this potentially deadly disease. Several companies are still looking to enter the coronavirus vaccine market, even though Pfizer and Moderna currently dominate it. One biotech that is slowly advancing a coronavirus vaccine candidate is Vaxart (NASDAQ: VXRT).